Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
SEC ownership of Climb Bio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001768446.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
26/50
Latest evidence
02 Jul 2026
- Public ticker
- CLYM on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
RA CAPITAL MANAGEMENT, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
26 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
RA CAPITAL MANAGEMENT, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
02 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001768446
- Issuer location
- Wellesley Hills, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Climb Bio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
26/50
Latest evidence
02 Jul 2026
13D/G
3/4/5
13F
Lead comparable stake: 33%
24 rows are not safely comparable across share classes.
13D/G row: RA CAPITAL MANAGEMENT, L.P.
Showing 1-8 of 50 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 33%.
26 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 5
RA CAPITAL MANAGEMENT, L.P.
33%
FMR LLC
12%
Pontifax Management 4 G.P. (2015)...
7.7%
MPM BioImpact LLC
5.6%
BlackRock, Inc.
4.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
3/4/5
Director, 10%+ Owner
|
33%
|
$258,995,932
23,249,186 shares
|
+$6,882,125 | 02 Jul 2026 |
| FMR LLC |
13D/G
|
12%
|
$75,644,655
6,790,364 shares
|
$0 | 30 Jun 2026 |
| Pontifax Management 4 G.P. (2015) Ltd. |
13D/G
Pontifax VI G.P. L.P.
|
7.7%
|
$12,911,822
5,206,380 shares
|
$0 | 27 Jun 2024 |
| MPM BioImpact LLC |
13D/G
|
5.6%
|
$13,437,544
2,671,480 shares
|
$0 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
Company
|
4.1%
|
$30,707,531
2,354,872 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
1.2%
|
$8,955,507
686,772 shares
|
— | 30 Jun 2026 |
| NAN FUNG TRINITY (HK) Ltd |
13F
Company
|
0.63%
|
$4,702,928
360,654 shares
|
— | 30 Jun 2026 |
| TD ASSET MANAGEMENT INC |
13F
Company
|
0.47%
|
$3,483,010
267,102 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$506,736.
Buys
$779,626
Insiders: 1
Sells
$1,286,361
Insiders: 2
Net
-$506,736
Shares: +140,770
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 321,672
Shares: 180,902
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 30,902 | $0 | $406,979 | -$406,979 |
| 3-6 | 0 | 50,000 | $0 | $350,253 | -$350,253 |
| 6-9 | 321,672 | 100,000 | $779,626 | $529,129 | +$250,497 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 29 reporting-owner rows connected to Climb Bio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
29
Largest Forms 3/4/5 holder
AI ETI LLC
Net 12M change
-$506,735
Latest report
29 Jun 2026
Recent insider transactions for Climb Bio, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | See Footnotes | |||
| RA CAPITAL MANAGEMENT, L.P. | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | See Footnotes | |||
| Breanna Maurine Celebi | CLYM | Stock Option (Right to Buy) | Award | 70,284 | 70,284 | 29 Jun 2026 | Direct | |||
| Aoife Brennan | CLYM | Common Stock | Sale | -26% | $406,979 | $13.17 | -30,902 | 87,731 | 29 Jun 2026 | Direct |
| Aoife Brennan | CLYM | Common Stock | Options Exercise | 137.8% | 68,750 | 118,633 | 27 Jun 2026 | Direct | ||
| Aoife Brennan | CLYM | Restricted Stock Units | Options Exercise | -33.3% | -68,750 | 137,500 | 27 Jun 2026 | Direct | ||
| RA CAPITAL MANAGEMENT, L.P. | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | See Footnotes | |||
| RA CAPITAL MANAGEMENT, L.P. | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | See Footnotes | |||
| Ra Capital Management, L.P. | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | See Footnotes | |||
| Andrew David Levin | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | Direct | |||
| Kimberlee C. Drapkin | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | Direct | |||
| Douglas E. Williams | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | Direct | |||
| Alexander Cumbo | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | Direct | |||
| Stephen Basil Thomas | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | Direct | |||
| Judith Dunn | CLYM | Stock Option (Right to Buy) | Award | 40,000 | 40,000 | 05 Jun 2026 | Direct | |||
| RA CAPITAL MANAGEMENT, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 10.3% | 2,106,000 | 22,546,000 | 29 Apr 2026 | See footnotes | ||
| RA CAPITAL MANAGEMENT, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 10.3% | 2,106,000 | 22,546,000 | 29 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 10.3% | 2,106,000 | 22,546,000 | 29 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 10.3% | 2,106,000 | 22,546,000 | 29 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 10.3% | 2,106,000 | 22,546,000 | 29 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 10.3% | 2,106,000 | 22,546,000 | 29 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 10.3% | 2,106,000 | 22,546,000 | 29 Apr 2026 | See footnotes | ||
| Stephen Basil Thomas | CLYM | Common Stock | Sale | -9.54% | $114,289 | $7.01 | -16,313 | 154,657 | 26 Feb 2026 | Direct |
| Stephen Basil Thomas | CLYM | Common Stock | Sale | -16.5% | $235,964 | $7.00 | -33,687 | 170,970 | 25 Feb 2026 | Direct |
| Stephen Basil Thomas | CLYM | Common Stock | Sale | -4.66% | $58,141 | $5.81 | -10,000 | 204,657 | 13 Feb 2026 | Direct |
| Stephen Basil Thomas | CLYM | Common Stock | Sale | -29.5% | $470,988 | $5.23 | -90,000 | 214,657 | 12 Feb 2026 | Direct |
| Aoife Brennan | CLYM | Stock Option (Right to Buy) | Award | 700,000 | 700,000 | 06 Jan 2026 | Direct | |||
| Perrin Megan Wilson | CLYM | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 06 Jan 2026 | Direct | |||
| Susan Altschuller | CLYM | Stock Option (Right to Buy) | Award | 142,500 | 142,500 | 06 Jan 2026 | Direct | |||
| Cindy Driscoll | CLYM | Stock Option (Right to Buy) | Award | 100,000 | 100,000 | 06 Jan 2026 | Direct | |||
| Ra Capital Management, L.P. | CLYM | Common Stock | Purchase | 0.21% | $24,888 | $3.50 | 7,111 | 3,403,429 | 05 Jan 2026 | See footnotes |
| Ra Capital Management, L.P. | CLYM | Common Stock | Purchase | 3.08% | $290,181 | $2.86 | 101,462 | 3,396,318 | 12 Dec 2025 | See footnotes |
| Ra Capital Management, L.P. | CLYM | Common Stock | Purchase | 6.91% | $464,556 | $2.18 | 213,099 | 3,294,856 | 11 Dec 2025 | See footnotes |
| Ra Capital Management, L.P. | CLYM | Common Stock | Disposed to Issuer | -86.9% | -20,440,000 | 3,081,757 | 11 Dec 2025 | See footnotes | ||
| Ra Capital Management, L.P. | CLYM | Pre-Funded Warrants (Right to Buy) | Award | 20,440,000 | 20,440,000 | 11 Dec 2025 | See footnotes | |||
| Susan Altschuller | CLYM | Stock Option (Right to Buy) | Award | 600,000 | 600,000 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.